- Lobe Sciences (LOBE) has incorporated its wholly owned Australian subsidiary to facilitate three or more clinical trials
- Lobe Sciences Australia is partnering with iNGENu to evaluate Lobe’s proprietary psilocin analogues L-130 or L-131
- The company has exclusive rights to source L-130 and other related compounds for clinical trials this year and even trials investigating new clinical indications in the future
- Lobe Sciences Ltd. (LOBE) is up 8.70 per cent, trading at C$0.125 per share at 1:10 pm ET
Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Lobe Sciences Australia is partnering with iNGENu to evaluate Lobe’s proprietary psilocin analogues L-130 or L-131.
The clinical trials are expected to begin late this year or early next year, depending on local regulatory approval.
The company has exclusive rights to source L-130 and other related compounds for clinical trials this year and even trials investigating new clinical indications in the future. Lobe could also earn a 43.5 per cent rebate from the Australian Federal Government’s Research and Development tax incentive program.
The company’s Chief Executive Officer, Philip J. Young, commented that the team is moving its proprietary stable psilocin products into human clinical trials on track with their business plan.”
Lobe Sciences (LOBE) is a Canadian biopharmaceutical company focused on discovering and developing psychedelic-derived medicines for neurologic and brain diseases.
Lobe Sciences Ltd. (LOBE) is up 8.70 per cent, trading at C$0.125 per share at 1:10 pm ET.
